title: A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers.
abstract: In a double-blind placebo controlled trial intranasal NPC 567, a bradykinin antagonist, failed to alleviate the symptoms of experimental rhinovirus colds. Indeed, there was evidence that the drug enhanced the symptoms although no irritant effect was detected on the uninfected nasal mucosa.
authors.affiliation: MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
authors.forename: P G
authors.initials: PG
authors.lastname: Higgins
authors.forename: G I
authors.initials: GI
authors.lastname: Barrow
authors.forename: D A
authors.initials: DA
authors.lastname: Tyrrell
mesh_terms: D000328:Adult; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D003139:Common Cold / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010850:Picornaviridae Infections / Q000188:drug therapy*; D012229:Rhinovirus
chemical_list: C053010:NPC 567; D001920:Bradykinin